DeviceSpace.com
Medical Device and Diagnostics
News & Jobs
 
Search the Site
    
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login  

Medical Device Companies | Diagnostic Companies | Organizations | Search Profiles
 Company Profile

 

Amira Pharmaceuticals, Inc. 

9535 Waples Street
Suite 100
San Diego  California  92121  U.S.A.
Phone: 858-228-4650 Fax: 858-558-8445


SEARCH JOBS


Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a privately held small molecule pharmaceutical company focused on the discovery and early development of compounds to treat inflammatory disease. The company combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient and effective pre-clinical and clinical program decisions. Its scientific founders have successfully worked together for more than a decade and were pivotal in the discovery of a number of inflammatory drugs, including Singulair®. The drug hunters at Amira are now actively leveraging their history of success to create high-value compounds for the future.


 Key Statistics


Email: info@amirapharm.com
Ownership: Private

Web Site: Amira Pharmaceuticals, Inc.
Employees: 50
Symbol: 
 




Segment
Start Up





 Company News
Panmira Pharmaceuticals, LLC. and FLAP LLC Spun Out of Amira Pharmaceuticals, Inc. 9/8/2011 3:00:17 PM    More...
Bristol-Myers Squibb Company (BMY) Completes Acquisition of Amira Pharmaceuticals, Inc. 9/8/2011 10:51:38 AM    More...
Bristol-Myers Squibb Company (BMY) to Pay Up to $475 Million for Amira Pharmaceuticals, Inc., Scoops Up Lung Drug 7/22/2011 6:32:43 AM    More...
Amira Pharmaceuticals, Inc. Announces Completion of Phase 1 Clinical Study for AM152, A Novel LPA1 Receptor Antagonist 5/2/2011 9:17:44 AM    More...
Amira Pharmaceuticals, Inc. Receives Orphan Drug Status for a Novel LPA1 Antagonist, AM152, for the Treatment of Idiopathic Pulmonary Fibrosis 4/19/2011 7:32:48 AM    More...
Findings Published in Journal of Pharmacology and Experimental Therapeutics Demonstrate Potential for Amira Pharmaceuticals, Inc.'s LPA1 Receptor Antagonist as an Anti-Fibrotic Agent 1/5/2011 9:13:32 AM    More...
Amira Pharmaceuticals, Inc. Announces the Nomination of an Orally Available Pre-Clinical Candidate in a New LPA-Related Program, an Autotaxin Inhibitor 12/15/2010 11:12:11 AM    More...
Amira Pharmaceuticals, Inc. to Present Preclinical, Clinical Data from DP2 Receptor Antagonist Program at Pacifichem 2010 12/14/2010 10:51:02 AM    More...
Amira Pharmaceuticals, Inc. Cuts Half of Staff, Scientific Founders Exit as Company Seeks to Conserve Cash 11/24/2010 7:04:47 AM    More...
Amira Pharmaceuticals, Inc. Announces Initiation of Phase I Clinical Trial for AM152, A Novel LPA1 Antagonist 10/28/2010 10:42:30 AM    More...
1234